Dyslipidemia

Total CV Event Reduction More Effectively Assesses Alirocumab Efficacy After ACS

Total CV Event Reduction More Effectively Assesses Alirocumab Efficacy After ACS

By

Total cardiovascular event reduction may represent a more comprehensive metric to assess alirocumab clinical efficacy after acute coronary syndrome.

Updated Guidelines Stress Healthy Lifestyle for Cholesterol Management

Updated Guidelines Stress Healthy Lifestyle for Cholesterol Management

A healthy lifestyle for lowering cholesterol should be emphasized for reducing cardiovascular risk across the life course, according to a guideline.

Ezetimibe Plus Statin Therapy Yields Greater Cost-Savings vs Evolocumab

Ezetimibe Plus Statin Therapy Yields Greater Cost-Savings vs Evolocumab

By

Compared with evolocumab, the addition of ezetimibe to statin therapy is a major cost-saving strategy for preventing cardiovascular (CV) death in patients with T2D and an established CV disease.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Therapy Examined

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Therapy Examined

By

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

Predictors of Statin Discontinuation Among Older Adults

Predictors of Statin Discontinuation Among Older Adults

First-year nonadherence and discontinuation are high among older adults prescribed statins.

LDL-C Testing Associated With Lower Achieved LDL-C Levels

LDL-C Testing Associated With Lower Achieved LDL-C Levels

By

Investigators sought to determine whether clinician lipid testing practices were consistent with ACC/AHA 2013 recommended testing guidelines for LDL cholesterol.

Plasma Lipid Genetic Variants Associated With Response to Niacin

Plasma Lipid Genetic Variants Associated With Response to Niacin

By

Genes most frequently associated with treatment-related changes in lipid traits were MVK, LIPC, PABPC4, AMPD3, SPTLC3, PDXDC1, and CYP26A1.

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

By

Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

By

Repatha is a proprotein convertase subtilisin/kexin type 9 inhibitor.

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

By

In multivariable models, associations were observed between cardiovascular risk factors and cerebrovascular morphology, as well as white matter hyperintensity count.

Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy

Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy

By

Supplementation with coenzyme Q10 may be an effective approach for managing statin-induced myopathy.

Triglyceride-Lowering Alleles Associated With Reduced Coronary Artery Disease Risk

Triglyceride-Lowering Alleles Associated With Reduced Coronary Artery Disease Risk

By

Triglyceride-lowering variants in the lipoprotein lipase pathway are independently associated with protection from coronary artery disease and type 2 diabetes.

Shared Financial Incentives Cost-Effective for Controlling LDL-C Levels

Shared Financial Incentives Cost-Effective for Controlling LDL-C Levels

By

Implementing shared financial incentives between physicians and patients is a cost-effective intervention strategy for controlling LDL-C levels among high-risk patients.

FDA to Review Praluent as Potential Treatment for MACE Risk Reduction

FDA to Review Praluent as Potential Treatment for MACE Risk Reduction

By

The sBLA is supported by data from the Phase 3 ODYSSEY OUTCOMES trial which included 18,924 patients who had experienced an acute coronary syndrome (ACS) in the previous 12 months.

Familial Hypercholesterolemia Benefits From Genetic Screening

Familial Hypercholesterolemia Benefits From Genetic Screening

By

Genetic screening for familial hypercholesterolemia would improve the likelihood of a definitive diagnosis and may help clinicians choose the appropriate therapy for patients.

FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome

FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome

By

"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.

Alirocumab Labeling Updated With Dosing for HeFH Patients Undergoing LDL Apheresis

Alirocumab Labeling Updated With Dosing for HeFH Patients Undergoing LDL Apheresis

By

The dosing recommendation was based on data from a double-blind, placebo-controlled study conducted in 62 patients with HeFH undergoing LDL apheresis.

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

By

Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.

Vitamin D Independently, Inversely Tied to Cholesterol in Children

Vitamin D Independently, Inversely Tied to Cholesterol in Children

Gene variants did not modify the associations of 25(OH)D with lipids.

Patient Connectivity Benefits Familial Chylomicronemia Syndrome

Patient Connectivity Benefits Familial Chylomicronemia Syndrome

By

Patients with familial chylomicronemia syndrome who were actively connected were also 3 times as likely to report "high" or "extremely high" motivation in managing their own health.

Idiopathic inflammatory myositis linked to statin exposure

In a case-control study, patients with histologically-confirmed idiopathic inflammatory myositis were more likely to report exposure to statin medications than population-matched controls.

Statin Prescribing Has Increased With Automated Patient Dashboard

Statin Prescribing Has Increased With Automated Patient Dashboard

Modest increase in statin prescribing with automated dashboard using active choice framing for primary care physicians.

Unfavorable Prepregnancy Lipid Levels Linked to Low Parity

Unfavorable Prepregnancy Lipid Levels Linked to Low Parity

Higher prepregnancy triglyceride levels and triglyceride high-density lipoprotein cholesterol ratios were linked to increased risk for one lifetime pregnancy.

Preeclampsia, Gestational Hypertension Increases CVD Risk Later in Life

Preeclampsia, Gestational Hypertension Increases CVD Risk Later in Life

By

Women with preeclampsia or gestational hypertension during their first pregnancy were more likely to report increased rates of subsequent chronic hypertension, type 2 diabetes, and hypercholesterolemia compared with women who were normotensive.

Statin Use and Cardiovascular Risk Perception Varies Among Races

Statin Use and Cardiovascular Risk Perception Varies Among Races

By

African American patients were less likely than white patients to be treated with any statin and at the guideline-recommended intensity.

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

Increased Arterial Stiffness Observed in Patients With Systemic Lupus Erythematosus

Increased Arterial Stiffness Observed in Patients With Systemic Lupus Erythematosus

By

Patients with systemic lupus erythematosus exhibit increased central arterial stiffness compared with a healthy control population.

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

By

For this study, researchers investigated the pharmacodynamics of evolocumab in two Phase 2 placebo-controlled studies (MENDEL and LAPLACE-TIMI 57) in order to determine which dosing regimens provided the most consistent LDL-C reduction.

Intensive LDL-C lowering reduces mortality in patients with higher baseline LDL-C

More intensive compared with less intensive LDL-C lowering therapy was associated with a greater risk reduction for total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.

Sign Up for Free e-Newsletters